Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEAR QD: Raltegravir Substitution for Dolutegravir in HIV
NCT03732625Phase 4Unknown
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of raltegravir in human immunodeficiency virus infection (HIV). Primary endpoint: Improvement in neuropsychiatric symptoms (DAIDS) at 12 weeks. Status: unknown.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03732625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732625.